Mohamed Kharfan-Dabaja, MD, MBA

About Dr.Kharfan-Dabaja

Dr. Kharfan-Dabaja, is a distinguished hematologist and oncologist at Mayo Clinic in Jacksonville, Florida, where he serves in the Blood and Marrow Transplant (BMT) and Cellular Therapy programs, including CAR-T cell therapy. Renowned for his expertise in hematologic malignancies and advanced cellular treatments, Dr. Kharfan-Dabaja provides individualized, evidence-based care to patients undergoing stem cell transplantation and immunotherapy.

He earned his medical degree from the American University of Beirut in Lebanon and completed his residency in internal medicine at the State University of New York–Stony Brook. He then pursued a fellowship in hematology and medical oncology at the University of Miami/Jackson Memorial Hospital. He is board-certified in Internal Medicine and Hematology by the American Board of Internal Medicine.

With more than two decades of experience in academic and clinical medicine, Dr. Kharfan-Dabaja has authored over 400 peer-reviewed manuscripts and 21 book chapters. His scholarly contributions span a wide range of topics, including allogeneic hematopoietic stem cell transplantation, CAR-T cell therapies, graft-versus-host disease, and evidence-based guidelines in transplant medicine. He frequently presents his work at national and international scientific forums and serves as a reviewer and editorial board member for leading medical journals.

A trilingual physician fluent in Arabic, English, and Spanish, Dr. Kharfan-Dabaja is committed to inclusive and compassionate care for patients of diverse backgrounds. He also contributes to global health initiatives, particularly in improving cancer care delivery and transplant access in low- and middle-income countries.

Outside of his medical career, Dr. Kharfan-Dabaja enjoys traveling and reading, which reflect his lifelong commitment to learning and cross-cultural understanding.

Articles by Mohamed Kharfan-Dabaja, MD, MBA

Mohamed Kharfan-Dabaja, MD, MBAT-Cell Lymphoma | June 7, 2025
Experts discuss T-cell lymphoma care, new therapies, transplant timing, and the role of NGS in treatment decisions.
View More
Rahul Banerjee, MD, FACPAggressive B-Cell Lymphoma | June 9, 2025
Experts explore CAR T therapy challenges and the future of lymphoma care beyond CD19-targeted treatments.
Ryan W. Jacobs, MDChronic Myeloid Leukemia | May 22, 2025
Experts debate frontline CLL therapy—time-limited combos vs long-term BTKi—and the role of MRD in treatment decisions.